



Changes to the Laboratory National Coverage Determination (NCD) Edit Software for January 2023

MLN Matters Number: MM12888 **Revised** Related Change Request (CR) Number: 12888

Related CR Release Date: **November 10, 2022** Effective Date: January 1, 2023

Related CR Transmittal Number: **R11700CP** Implementation Date: January 3, 2023

Note: We revised this Article due to a revised CR 12888. The CR revision didn't affect the substance of the Article. We did revise the CR release date, transmittal number, and the web address of the CR. All other information is the same.

Provider Types Affected

This MLN Matters Article is for laboratories billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients.

Provider Action Needed

Make sure your billing staff knows about:

- Changes to the Laboratory NCD Edit Module for January 2023
- How to access the NCD spreadsheet that lists relevant changes

Background

This Article tells you of changes in the January 2023 quarterly release of the edit module for clinical diagnostic laboratory services. CMS updates the laboratory edit module as necessary to reflect coding updates and substantive changes to NCDs. The laboratory negotiated rulemaking committee developed the NCDs for clinical diagnostic laboratory services.

The NCDs with coding updates in January are:

- Urine Culture, Bacterial (190.12)
- Human Immunodeficiency Virus (HIV) Testing (Prognosis Including Monitoring) (190.13)
- Blood Counts (190.15)
- Partial Thromboplastin Time (PTT) (190.16)
- Prothrombin Time (PT) (190.17)
- Serum Iron Studies (190.18)
- Collagen Crosslinks, Any Method (190.19)

- Blood Glucose Testing (190.20A and 190.20)
- Glycated Hemoglobin/Glycated Protein (190.21)
- Thyroid Testing (190.22)
- Lipids Testing (190.23A and 190.23B)
- Digoxin Therapeutic Drug Assay (190.24)
- Alpha-fetoprotein (190.25)
- Carcinoembryonic Antigen (190.26)
- Human Chorionic Gonadotropin (190.27)
- Tumor Antigen by Immunoassay CA 125 (190.28)
- Tumor Antigen by Immunoassay CA 15-3/CA 27.29 (190.29)
- Tumor Antigen by Immunoassay CA 19-9 (190.30)
- Prostate Specific Antigen (190.31)
- Gamma Glutamyl Transferase (190.32)
- Hepatitis Panel/Acute Hepatitis Panel (190.33)
- Fecal Occult Blood Test (190.34)

The [NCD spreadsheet](#) shows the changes for these NCDs.

More Information

We issued [CR 12888](#) to your MAC as the official instruction for this change.

For more information, [find your MAC's website](#).

Document History

Date of Change	Description
November 10, 2022	We revised this Article due to a revised CR 12888. The CR revision didn't affect the substance of the Article. We did revise the CR release date, transmittal number, and the web address of the CR. All other information is the same.
September 6, 2022	Initial article released.

[Medicare Learning Network® Content & Product Disclaimer, and Department of Health & Human Services Disclosure](#)

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).